Biologic therapies, particularly TNF inhibitors, were also shown to reduce the risk of developing PsA in patients with psoriasis.[22] One study reported a hazard ratio (HR) of 0.46 for biologics compared to methotrexate. Here, TNF is linked to psoriasis.